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Abstract
Background
Both motor and non-motor symptoms could contribute to significant deterioration of psycho-
logical well-being in patients with Parkinson’s disease (PD). However, its assessment has
been only indirectly evaluated using tools based on health-related quality of life (HRQoL),
such as the PDQ-39 scale.
Objectives
To evaluate psychological well-being in PD using a specific tool of assessment, the Psycho-
logical Well-being Scale (PWS), and its clinical correlates.
Methods
This article reports data of patients’ perception of health state, as measured by means of the
PWS, from an epidemiological, cross-sectional study conducted in Italian PD patients
(FORTE Study). We tested possible relationship between well-being and clinical character-
istics including fatigue, depression, sleep disruption and HRQoL.
Results
272 patients completed the PWS questionnaire. Significant and clinically-relevant correla-
tions were found between PWS total score and Parkinson’s Fatigue Scale, Beck Depression
Inventory, UPDRS Section I, PD Sleep Scale and PDQ-39 for HRQoL scores. Only clinically
negligible correlations were found between PWS and motor scores.
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Conclusions
Non-motor symptoms have a significant impact on psychological well-being in PD patients.
Introduction
Parkinson’s disease (PD) is a progressive disorder associated with a wide range of motor and
non-motor symptoms that contribute to significant disability and deterioration of health-
related quality of life (HRQoL) [1,2].
In 1948 the World Health Organization’s (WHO) defined “health” in terms of “physical,
mental, and social well-being, and not merely the absence of disease and infirmity” [3]. The
term “subjective well-being” or “happiness” is often used to refer to a combination of the
absence of negative emotions and the presence of positive emotions, life satisfaction, and social
engagement [4]. While HRQoL represents a broad concept which includes the physical state of
health as well as social-economic factors, in accordance with the concept of “health”, well-
being is particularly related with the psychological dimension, as reinforced by the definition
of “mental health” proposed for the WHO [5,6].
“Well-being” is now commonly proposed as a theme for outcome measures as it reflects the
expanded goals of treatment, from medical treatment toward broader health care. Several reli-
able ways of measuring well-being are available, including measures that focus on the presence
of positive emotions and the absence of negative emotions, life satisfaction [7], social engage-
ment [8], and physical wellness [9]. Such measures of subjective well-being emphasize the
importance of the hedonic aspects of experience, such as pleasure, satisfaction, and happiness
[10].
Treatment of PD has traditionally focused on the improvement of motor symptoms. More
recently, treatment has widened to include also non-motor symptoms. Even if the measure-
ment of quality of life using specific scale, such as the PDQ-39 [11], has become a common
endpoint in almost all the clinical trials as well as observational studies recently carried out,
few studies have systematically investigated the well-being in terms of positive emotions and
life satisfaction. There is still a need for specific indicators to be used in clinical trials targeting
on health state perception in PD, which differ from the other common indicators of quality of
life. This is crucial for quantifying possible specific therapeutic interventions on psychological
well-being in PD.
The objective of the present study is to evaluate psychological well-being and positive func-
tioning in a large sample of PD patients from an observational, cross-sectional, multicentre
study carried out in Italy (i.e. the FORTE study) [12], in order to identify factors possibly
related to a better “well being”.
Methods
The FORTE study plan included a cross-sectional single visit during which all information was
collected. The study population included adult outpatients of either sex with idiopathic PD
diagnosed according to the U.K PD Society brain bank diagnostic criteria for PD [13], includ-
ing new diagnosed patients. Exclusion criteria included the presence of any type of dementia
(DSM-IV criteria) [12]. The demographic and general characteristics of study participants
have been previously reported [12]. Briefly, the study was conducted in 27 sites in Italy
between March and June 2011. A total of 402 patients were screened and all were eligible for
inclusion into the study (245 men, 60.9%; age 66.9±8.9 years; disease duration 7.5±5.6 years).
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The following data were recorded at the study visit: patient demographics, medical history
(onset and duration of PD), presence of co-morbidities and associated treatments, severity of
PD according to the modified Hoehn-Yahr scale. Psychological well-being was evaluated using
the psychological well being scales (PWS), a standardized non-disease specific instrument
[14,15], already validated in Italian language [16]. PWS is a 84 item self-rating inventory, mea-
suring six multiple facets of psychological well-being (14 items for each dimension): “auton-
omy”, “environmental mastery”, “personal growth”, “positive relations”, “purpose in life” and
“self-acceptance”. Patients reported their degree of agreement ranging from 1 (disagree) to 6
(fully agree), with negative items counted inversely to obtain a final score for each domain, in
which higher scores are indicative of better outcome.
The degree of fatigue was evaluated using the 16-items Parkinson’s Fatigue Scale (PFS)
[17], a patient-rated scale exploring physical aspects of fatigue and its impact on daily func-
tioning, which is based on 16 items ranging from 1 (strongly disagree) to 5 (strongly agree),
with the PFS-16 mean score being calculated as the mean of all individual item scores [12,17].
Other measures used in the study included the Unified Parkinson’s Disease Rating Scale
(UPDRS) for motor assessment [18], the Parkinson’s disease questionnaire-39 item version
(PDQ-39) for quality of life [19], the Beck Depression Inventory (BDI) [20] for depression and
the Parkinson’s Disease Sleep Scale (PDSS) for sleep disorders [21]. All evaluations were per-
formed together with the UPDRS, which was administered during the”ON” phase.
The study protocol was approved by the Ethics Committee of the coordinating centre
(Comitato Etico IRCCS San Raffaele Pisana, Rome) and each of the participating sites. All
patients provided written informed consent prior to any study-related procedure was started.
Statistical analysis
The comparison between groups for continuous parameters was performed by means of
Mann-Whitney test. The analysis of variance (ANOVA) was also used to compare more than
two independent mean groups for quantitative parameters. The pairwise comparisons were
done applying the Scheffe’s method when the p-value associated to the F-test of the ANOVA
was statistically significant.
A multiple linear regression analysis model was also used to assess the relationship between
PWS total score and the following variables: age, age at diagnosis for PD, duration of disease,
Hoehn-Yahr stage, PDSS total score, BDI total score, PFS-16 mean score, PDQ-39 total score,
UPDRS total score and the subtotal scores for the Sections I-IV. In this model, a backward pro-
cedure with a cut-off of p = 0.10 was applied to select the variables to be removed. Pearson cor-
relation coefficients (r) were computed to estimate the linear relationship between the PWS
total score and the above variables. As role of thumb, correlation coefficients between -0.3 and
0.3 were considered clinically negligible [22]. The statistical testing was conducted at the two-
sided α = 0.05 level.
Results
Overall 272 PD patients completed the PWS questionnaire. The age was 66.2±9.4 years (range
37–89) and approximately 65% of patients were females. The duration of the disease was 7.3
±5.8 years (range 1–40).
The mean (±SD) PWS total score in the overall evaluable population was 348.7±46.2
(median 350, range 222–454). Table 1 shows the results of PWS as total score and in each
dimension of health in the overall evaluable population. The level of impairment was compara-
ble in each domain, with mean values ranging from 55.7 for personal growth to 60.2 for
autonomy.
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Distribution of the PWS score by gender, age class, educational level, stage of the disease
and current treatment for PD are showed in Table 2. The difference between genders (p =
0.358) and education level groups (p = 0.473) were not statistically significant. The mean PWS
total score in patients aged 70–74 years was significantly higher than that of those aged75
Table 1. Results of PWS total and single domains scores.
PWS total score 348.72 ± 46.19 (222–454)
Autonomy 60.18 ± 8.60 (35–84)
Environmental mastery 56.98 ± 9.51 (32–83)
Personal growth 55.74 ± 8.22 (28–80)
Positive relations 60.03 ± 10.21 (26–83)
Purpose in life 57.33 ± 9.56 (28–78)
Self-acceptance 58.46 ± 10.65 (19–82)
Notes: Data are mean ± SD (range).
https://doi.org/10.1371/journal.pone.0189682.t001
Table 2. PWS total score by demographic and baseline clinical characteristics.
No. of patients Mean ± SD Median Range (min-max)
Gender
Males 94 351.4 ± 46.6 352.50 226–454
Females 178 344.6 ± 45.8 348.50 222–435
Age class (years) *
<60 57 358.4 ± 47.5 364.0 222–454
60–64 52 347.8 ± 46.5 349.5 226–446
65–69 55 340.3 ± 40.3 340.0 235–435
70–74 61 362.1 ± 44.9 366.0 238–434
75 47 332.2 ± 47.5 334.0 245–448
Education Level
None/First level 77 355.5 ± 44.0 356.0 239–435
Second Level 80 343.9 ± 52.3 347.5 222–454
High school 83 348.5 ± 42.0 348.0 226–445
University 32 347.6 ± 47.1 347.0 245–448
Hoehn & Yahr scale **
Stage 1 71 364.9 ± 48.1 375.0 256–454
Stage 2 129 342.7 ± 43.8 344.0 226–446
Stage 3 66 346.8 ± 44.8 348.5 222–435
Stage 4 6 320.0 ± 56.3 326.0 254–385
Current treatment for PD †
MAOIs 107 357.7 ± 45.3 359.0 226–454
Dopamine agonist 182 352.8 ± 44.3 355.0 222–454
Levodopa 207 345.3 ± 46.4 345.0 222–448
Amantadine 11 346.6 ± 40.0 342.0 285–391
Anticholinergic drugs 7 332.7 ± 44.5 322.0 277–399
Notes
*p value (F-value test) = 0.004. Difference between age 70–74 and 75 years: 29.96 (95% CI: 2.66 to 57.26); NS in the other pairwise comparisons.
**p value (F-value test) = 0.004. Difference between Stage 1 and Stage 2: -22.20 (95% CI: -35.42 to -8.98); difference between Stage 1 and Stage 3–4:
31.54 (95% CI: 9.70 to 53.37); NS in the other pairwise comparisons.
† A patient may be counted in more than one drug category.
https://doi.org/10.1371/journal.pone.0189682.t002
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years, without statistically significant differences between the other age ranges, as well as in
the comparison between patients aged70 years (351.22±45.03) and those aged>70 years
(344.82±48.71) (p = 0.370). Patients with stage 1 of the Hoehn-Yahr scale showed a higher
mean PWS total score than the other stages of the scale (significantly vs. stage 2 and pooled
stage 3–4). Although patients treated with monoamine oxidase inhibitors (MAOIs) had a
higher mean PWS total score than the other drug classes, the difference by category of current
treatments for PD was not statistically significant (p = 0.133).
Results of the correlation tests are summarized in Table 3. A direct correlation was found
between PWS total score and PDSS total score (r = 0.349, p<0.0001), while a moderate inverse
correlation was found between PWS total score and the following variables: PFS total score
(r = -0.398, p<0.0001); BDI total score (r = -0.569, p<0.0001); PDQ-39 total score (r = -0.544,
p<0.0001) and UPDRS Section I (r = -0.488, p<0.0001). Less evident correlations were found
between PWS total score and the other UPDRS sections, as well as with the severity of the dis-
ease (Hoehn-Yahr scale), whereas PWS total score resulted to be not related with and age at
diagnosis of PD and duration of disease. The “environmental mastery” was the PWS dimen-
sion of health most strongly correlated with the severity of non-motor symptoms, showing
also a moderate inverse correlation with UPDRS total and UPDRS Section II scores.
Selected predictive variables (age, age at diagnosis for PD, duration of disease, Hoehn-Yahr
stage, PDSS total score, BDI total score, PFS-16 mean score, PDQ-39 total score, UPDRS total
and subtotal scores for the Sections I-IV) were then included in the regression analysis setting
PWS total score as dependent variable. After ten step of backward elimination the following
Table 3. Results of correlation tests.
PWS total Autonomy Environmental
mastery
Personal
growth
Positive
relations
Purpose in life Self acceptance
Duration of PD r: -0.104
p = 0.087
r: -0.036
p = 0.561
r: -0.128 p = 0.035 r: -0.061
p = 0.321
r: -0.084
p = 0.167
r: -0.130
p = 0.033
r: -0.064
p = 0.291
Age at
diagnosis
r: -0.024
p = 0.693
r: -0.021
p = 0.729
r: 0.044 p = 0.474 r: -0.188
p = 0.002
r: 0.003
p = 0.961
r: -0.064
p = 0.291
r: 0.074
p = 0.226
Hoehn & Yahr r: -0.177
p = 0.003
r: -0.081
p = 0.183
r: -0.200 p = 0.001 r: -0.153
p = 0.012
r: -0.122
p = 0.045
r: -0.177
p = 0.003
r: -0.131
p = 0.031
PFS total r: -0.398
p<0.001
r: -0.236
p<0.001
r: -0.437 p<0.001 r: -0.261
p<0.001
r: -0.241
p<0.001
r: -0.442
p<0.001
r: -0.314
p<0.001
BDI total r: -0.569
p<0.001
r: -0.364
p<0.001
r: -0.564 p<0.001 r: -0.357
p<0.001
r: -0.403
p<0.001
r: -0.555
p<0.001
r: -0.511
p<0.001
UPDRS total r: -0.262
p<0.001
r: -0.143
p = 0.021
r: -0.306 p<0.001 r: -0.143
p = 0.021
r: -0.073
p = 0.005
r: -0.299
p<0.001
r: -0.205
p = 0.001
UPDRS Section
1
r: -0.488
p<0.001
r: -0.212
p = 0.001
r: -0.487 p<0.001 r: -0.351
p<0.001
r: -0.355
p<0.001
r: -0.510
p<0.001
r: -0.444
p<0.001
UPDRS Section
2
r: -0.241
p<0.001
r: -0.117
p = 0.058
r: -0.320 p<0.001 r: -0.103
p = 0.095
r: -0.151
p = 0.014
r: -0.270
p<0.001
r: -0.199
p = 0.001
UPDRS Section
3
r: -0.176
p = 0.004
r: -0.113
p = 0.063
r: -0.194 p = 0.001 r: -0.097
p = 0.111
r: -0.115
p = 0.060
r: -0.214
p = 0.000
r: -0.121
p = 0.048
UPDRS Section
4
r: -0.153
p = 0.013
r: -0.040
p = 0.518
r: -0.215 p = 0.000 r: -0.062
p = 0.315
r: -0.087
p = 0.159
r: -0.186
p = 0.002
r: -0.140
p = 0.022
PDSS total r: 0.349
p<0.001
r: 0.184
p = 0.003
r: 0.372 p<0.001 r: 0.219
p = 0.001
r: 0.286 p<0.001 r: 0.306
p<0.001
r: 0.310 p<0.001
PDQ total r: -0.544
p<0.001
r: -0.330
p<0.001
r: -0.539 p<0.001 r: -0.330
p<0.001
r: -0.413
p<0.001
r: -0.514
p<0.001
r: -0.488
p<0.001
Notes: data are Pearson’s correlation coefficients (r) and p values. Pearson’s r indicative of an at least moderate inverse or direct correlation (i.e. -0.3
or 0.3) are highlighted in bold.
https://doi.org/10.1371/journal.pone.0189682.t003
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variables were kept in the regression model: BDI total score (coefficient: -1.725, S.E. 0.418,
p<0.0001), PDQ-39 total score (coefficient: -0.928, S.E. 0.231, p<0.0001) and the UPDRS sec-
tion I (coefficient: -4.841, S.E. 1.625, p = 0.0032) (ANOVA F = 36.46, p<0.0001; goodness of
fit: R2 = 0.3794).
Discussion
The main findings of our analysis have shown a mean PWS score indicative of a moderate
impairment of psychological well-being and positive functioning in the cohort of PD patients
that took part in the cross-sectional Italian FORTE study [12] and completed the PWS ques-
tionnaire. The level of well-being was comparable across the six dimensions of health, in line
with the high correlation coefficients between each of them reported by both the developers of
the scale [15] and in the Italian validation of PWS [16].
PWS total and domains mean scores were shown also to be not correlated with age, disease
duration and motor symptoms. Conversely, the mean score of PWS overall and in each dimen-
sion of health resulted to be inversely correlated with the severity of fatigue and depression,
and was directly correlated with the extent of sleep disruption. Overall, these findings were
indicative of a worsened psychological well-being in patients with higher impairments of
health state. As further evidence of the influence of the mood and cognitive components on
the psychological perception of well-being, important correlations were found between almost
all PWS dimensions (except for autonomy) and the “Mentation, Behavior, and Mood” section
score of the UPDRS. The “environmental mastery”, that is defined as the ability to manage
complex environments to suit personal needs and values, was the PWS dimension of health
most strongly correlated with the severity of non-motor symptoms.
The significant effect of BDI total score, PDQ-39 total score and the UPDRS section I in the
regression analysis model allowed building a model indicative of a moderate predictive effect
of the exploratory variables. The results of the stepwise multiple linear regression analysis were
comparable to those reported in other studies, in which UPDRS Section I (but not UPDRS
motor Section III) were kept in the model [23,24].
Overall, these findings provide a confirmatory evidence of previous data showing that neu-
ropsychiatric symptoms, especially depression, night-time sleep disorders, fatigue and somno-
lence, are the variables that most affect the HRQoL of patients with PD [24–26]. Thus, our
data demonstrate that non-motor symptoms are negatively associated with patients’ health
perception. Notably, the mean PWS total score and subscores were found to correlate with the
mean total score of the PDQ-39, which is the most used and validated disease-specific instru-
ment for self-reported health status in PD [27,28]. However, it should be noted that, differently
from PDQ-39, no clinically-relevant correlation between PWS and motor scores was detected,
being variables also excluded by the multiple linear regression model. As indicator of the over-
all concept of health, in fact, PDQ-39 score has shown to be dependent on patients motor sta-
tus, correlating with Hoehn-Yahr staging and total UPDRS motor score [21]. Psychological
well-being, and thus the patient’s health state perception, seems instead to be more dependent
on non-motor symptoms referred by patients with PD, including fatigue, depression and sleep
disruption. Nevertheless, some of these aspects, such as fatigue, could be due to other physical
factors related to motor symptoms, thus we cannot exclude motor components to be also asso-
ciated to psychological well-being in PD.
The cross-sectional design of the study may represent a principal limitation. Another study
limitation may be due to the inclusion of patients mainly in the early stages of the disease, that
may have contributed to the weak correlation between PWS total score and domains and the
Hoehn-Yahr score. Moreover, since about 38% of the variability of the PWS total score can be
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accounted for by the obtained linear regression model, we cannot exclude that other not-inves-
tigated factors may have contributed to PWS total score variability in the study population.
In conclusion, to the best of our knowledge this is the first study which evaluates psycholog-
ical well-being instead of common measures of QoL as indicator of health status in PD. The
results of our data suggest that the presence of non-motor symptoms, such as fatigue, depres-
sion and sleep disruption, have a significant impact on psychological well-being in PD patients.
Therefore, our findings confirm the previous evidence on the burden of non-motor symptoms
as a key determinant of psychological well-being in PD. Future studies are needed to evaluate
possible pharmacological interventions on psychological well-being in PD.
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